Skip to main content
. 2022 Mar 15;25:1–15. doi: 10.1016/j.omto.2022.03.004

Figure 3.

Figure 3

ARF6 knockdown could improve drug sensitivity of CCL18-stimulated MCF-7 cells

CCK-8 assay was carried out to analyze cell viability of MCF-7 cells in control, CCL18, CCL18 + si-NC, or CCL18 + si-ARF6-2 groups after treatment with increasing concentrations of (A) doxorubicin (0, 5, 10, and 20 μg/mL), (B) paclitaxel (0, 50, 100, and 200 nM), and (C) tamoxifen (0, 0.5, 1.0, and 5 μM), respectively. Cell apoptotic rate was determined using flow cytometry in MCF-7 cells in control, CCL18, CCL18 + si-NC, or CCL18 + si-ARF6-2 groups after treatment with 10 μg/mL doxorubicin (D), 100 nM paclitaxel (E), or 1 μM tamoxifen (F). Data were expressed as mean ± SD. ∗∗p < 0.01, compared with CCL18.